Dorit Cohen-Carmon
Chief Scientific Officer
Claimed by owner Ramino-Bio
Former names:
Treatment of Cardiometabolic Diseases Using Enhanced Branched-chain Amino Acids
Ramino-Bio
About
Ramino-Bio is developing treatments for cardiometabolic diseases by enhancing the branched-chain amino acids valine, leucine, and isoleucine through catabolism.
Diet, obesity, genetics, and gut microbiota can increase circulating BCAAs above the normal level, and chronically elevated levels of circulating BCAAs are known to be a propagating factor for cardiac hypertrophy, muscle lipid accumulation, hepatic lipid storage, and glycemia, contributing to various metabolic disorders.
Ramino-Bios strategy is to develop a drug designed to lower elevated BCAAs levels for metabolic disease therapy and as an intervention to halt the deterioration of cardiac function after heart failure, including for HFpEF patients.
The companys underlying technology originated from the lab of Professor Yibin Wang, chief of the molecular medicine department of anesthesiology, physiology, and medicine at the David Geffen School of Medicine at UCLA.
Ramino-Bio was founded at the FutuRx biotech incubator and is financed by the Israel Innovation Authority, Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation, and the RMGP Bio-Pharma Investment Fund.
Diet, obesity, genetics, and gut microbiota can increase circulating BCAAs above the normal level, and chronically elevated levels of circulating BCAAs are known to be a propagating factor for cardiac hypertrophy, muscle lipid accumulation, hepatic lipid storage, and glycemia, contributing to various metabolic disorders.
Ramino-Bios strategy is to develop a drug designed to lower elevated BCAAs levels for metabolic disease therapy and as an intervention to halt the deterioration of cardiac function after heart failure, including for HFpEF patients.
The companys underlying technology originated from the lab of Professor Yibin Wang, chief of the molecular medicine department of anesthesiology, physiology, and medicine at the David Geffen School of Medicine at UCLA.
Ramino-Bio was founded at the FutuRx biotech incubator and is financed by the Israel Innovation Authority, Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation, and the RMGP Bio-Pharma Investment Fund.
Primary Sector
Life Sciences & HealthTech
Products
-
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
1
Investors
6
News
(0)The Team
(1)
DC
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Sep 2018
6 Investors
Undisclosed
Media gallery
(0)Locations
Israel
Ilan Ramon St 2, Ness Ziyyona, Israel
Locations
Israel
Ilan Ramon St 2, Ness Ziyyona, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,